SymBio Pharmaceuticals (TSE:4582) Total Stockholders Equity: 円-583 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4582 SymBio Pharmaceuticals Ltd TSE:4582
36 GF Score
Price 円55.00
GF Value 円51.83
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is SymBio Pharmaceuticals Total Stockholders Equity?

SymBio Pharmaceuticals TSE:4582 36 Total Stockholders Equity is 円-583 Mil as of Jun. 2026. GuruFocus rates TSE:4582 with a GF Score™ of 36/100 and a GF Value™ of 円51.83 (Fairly Valued). The stock has 5 warning signs investors should review.

SymBio Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Jun. 2026 was 円-583 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. SymBio Pharmaceuticals's Book Value per Share for the quarter that ended in Jun. 2026 was 円-7.63. The ratio of a company's debt over equity can be used to measure how leveraged this company is. SymBio Pharmaceuticals's Debt-to-Equity for the quarter that ended in Jun. 2026 was -1.43.

SymBio Pharmaceuticals  (TSE:4582) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

SymBio Pharmaceuticals's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-582.847-0)/76.342991
=-7.63

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

SymBio Pharmaceuticals's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(832.5 + 0) / -582.847
=-1.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SymBio Pharmaceuticals Total Stockholders Equity Related Terms

SymBio Pharmaceuticals Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for SymBio Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SymBio Pharmaceuticals Total Stockholders Equity Chart

SymBio Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,745.67 8,506.09 7,209.91 4,197.56 1,272.04

SymBio Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,364.00 1,652.47 1,272.04 231.69 -582.85
TSE:4582
36GF Score
SymBio Pharmaceuticals Ltd TSE:4582
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of 円-583 Mil mean?
SymBio Pharmaceuticals (TSE:4582) has a Total Stockholders Equity of 円-583 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for SymBio Pharmaceuticals and its competitors.
Is SymBio Pharmaceuticals' Total Stockholders Equity too high?
SymBio Pharmaceuticals' current Total Stockholders Equity is 円-583 Mil. Overall, SymBio Pharmaceuticals has a GF Score™ of 36/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does SymBio Pharmaceuticals' Total Stockholders Equity compare to ZTS?
SymBio Pharmaceuticals' Total Stockholders Equity of 円-583 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for SymBio Pharmaceuticals and its competitors. SymBio Pharmaceuticals's current Total Stockholders Equity is 円-583 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SymBio Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, SymBio Pharmaceuticals (TSE:4582) is currently considered Fairly Valued. The stock's GF Value™ is 円51.83, compared to a current price of 円55.00 — trading 6.1% above its estimated fair value. The current Total Stockholders Equity is 円-583 Mil. SymBio Pharmaceuticals' overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For SymBio Pharmaceuticals (TSE:4582), the current Total Stockholders Equity is 円-583 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SymBio Pharmaceuticals (TSE:4582) Overvalued in 2026?

Based on GuruFocus' analysis, SymBio Pharmaceuticals stock appears to be overvalued. The current stock price of 円55.00 is trading 6.1% above its estimated GF Value™ of 円51.83. GuruFocus considers SymBio Pharmaceuticals to be Fairly Valued.

Key valuation signals for TSE:4582:

  • Total Stockholders Equity: 円-583 Mil
  • GF Value™: 円51.83 vs. price of 円55.00 (6.1% above fair value)
  • GF Score™: 36/100 with 5 warning signs

No single metric tells the full story. See the TSE:4582 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SymBio Pharmaceuticals Business Description

Address 1-28 Toranomon 4-chome, 7th Floor, Toranomon Towers Office, Minato-ku, Tokyo, JPN, 105-0001
SymBio Pharmaceuticals Ltd is a biopharmaceutical company engaged in development of new drugs with a primary focus on the treatment of rare diseases, mainly in the areas of oncology, hematology and multiple viral infections, and conduct integrated business activities that encompass search for new drug candidates, development, manufacturing, and sales.
36GF Score

Get the complete analysis for TSE:4582

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円55.00
Price
円51.83
GF Value